The promising value of targeting the CD39-CD73-ADO cascade as an anti-tumor therapy has been further demonstrated by treatment of mice with an anti-CD73 antibody that curbs the development of lung metastases in a breast tumor model [120]. This evidence concerns the gene ENTPD1 and neoplasm.